Clinical trial

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

NCT01115803

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention LY2584702 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Erlotinib Normalized identity: erlotinibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Everolimus Normalized identity: everolimusView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2010-03-01

PhasePHASE1

Conditions

Metastases, Neoplasmunresolved

Carcinoma, Non-small Cell Lungcandidate · MONDO: non-small cell lung carcinoma

Renal Cell Carcinomaverified · MONDO: renal cell carcinoma

Neuroendocrine Tumorsunresolved

Interventions

LY2584702DRUG

ErlotinibDRUG · verified · RxNorm: erlotinib

EverolimusDRUG · verified · RxNorm: everolimus

Sponsors & collaborators

Eli Lilly and Companylead sponsor

Mapped research locations

ChicagoIllinois, United States1 BordeauxFrance1 VillejuifFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01115803 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.